22Nw LP Takes Position in Nektar Therapeutics (NASDAQ:NKTR)

22Nw LP acquired a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 2,191,750 shares of the biopharmaceutical company's stock, valued at approximately $2,038,000. Nektar Therapeutics makes up about 1.5% of 22Nw LP's holdings, making the stock its 13th largest holding. 22Nw LP owned about 1.19% of Nektar Therapeutics as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Nantahala Capital Management LLC lifted its holdings in shares of Nektar Therapeutics by 90.0% in the fourth quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company's stock valued at $7,263,000 after purchasing an additional 3,700,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Nektar Therapeutics by 17.5% in the 4th quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company's stock valued at $3,637,000 after buying an additional 583,153 shares in the last quarter. Altium Capital Management LLC grew its holdings in Nektar Therapeutics by 26,172.0% during the 4th quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company's stock valued at $2,790,000 after buying an additional 2,988,581 shares during the last quarter. Monaco Asset Management SAM increased its position in Nektar Therapeutics by 1.8% during the fourth quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company's stock worth $1,891,000 after buying an additional 35,648 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Nektar Therapeutics by 0.9% in the fourth quarter. Northern Trust Corp now owns 1,414,984 shares of the biopharmaceutical company's stock worth $1,316,000 after acquiring an additional 12,826 shares during the last quarter. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Stock Performance

Shares of NKTR stock opened at $0.78 on Friday. The firm has a market capitalization of $145.18 million, a price-to-earnings ratio of -0.93 and a beta of 0.69. Nektar Therapeutics has a one year low of $0.43 and a one year high of $1.93. The company has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.94.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The business had revenue of $29.18 million for the quarter, compared to analyst estimates of $36.65 million. As a group, equities analysts forecast that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research note on Thursday, March 13th. William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. Jefferies Financial Group raised shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their price objective for the company from $1.00 to $2.00 in a research report on Friday, April 11th. B. Riley started coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $4.00 target price on the stock. Finally, StockNews.com started coverage on Nektar Therapeutics in a report on Wednesday, April 16th. They issued a "hold" rating for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $4.50.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.